文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症:2024年诊断、风险分层和治疗更新

Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
PubMed 文献 · Am J Hematol · 2023-06-26

该综述更新了真性红细胞增多症(PV)的诊断、风险分层和治疗。PV为JAK2突变骨髓增殖性肿瘤,以克隆性红细胞增多为特征。诊断依据JAK2突变联合血红蛋白/血细胞比容阈值,骨髓形态学可辅助但不强制。治疗核心为放血使血细胞比容<45%联合阿司匹林81 mg,高危患者行降细胞治疗。

要点

  • 诊断工作前提:JAK2突变伴男性血红蛋白>16.5 g/dL或血细胞比容49%、女性血红蛋白16 g/dL或血细胞比容48%。
  • 所有患者治疗骨干为定期放血使血细胞比容<45%联合每日一次或两次阿司匹林81 mg(无禁忌时)。
  • 降细胞治疗用于高危患者,一线首选羟基脲或聚乙二醇干扰素α,二线为白消安或芦可替尼。

核心结论

  • 当前治疗目标是预防血栓形成。
  • 所有患者无论风险类别,均以放血联合阿司匹林为治疗骨干。
  • 降细胞治疗用于高危患者,一线首选羟基脲或聚乙二醇干扰素α,二线为白消安或芦可替尼。
  • 作者不将药物诱导的JAK2V617F等位基因负荷下降视为疾病修饰活性指标,除非伴有细胞遗传学和独立验证的形态学缓解,因此不用该参数影响治疗选择。

研究设计与样本

  • 该文为真性红细胞增多症2024年诊断、风险分层和治疗更新的综述。

主要发现

  • 中位生存期约15年,年龄≤40岁患者超过35年。
  • 20年血栓形成、真性红细胞增多症后骨髓纤维化(post-PV MF)或急性髓系白血病(AML)风险分别约为26%、16%和4%。
  • 15%-20%患者可见异常核型,最常见的单一异常为+9(5%)、Y染色体丢失(4%)、+8(3%)和20q-(3%)。
  • 超过50%患者携带JAK2以外的DNA序列变异/突变,最常见为TET2(18%)和ASXL1(15%)。
  • 不良预后突变包括SRSF2、IDH2、RUNX1和U2AF1,合计发生率为5%-10%。

关键数值与推荐

  • 诊断:JAK2突变伴男性血红蛋白>16.5 g/dL或血细胞比容49%、女性血红蛋白16 g/dL或血细胞比容48%时考虑工作诊断,建议但不强制骨髓检查形态学确认。
  • 血栓风险分层:高危为年龄>60岁或血栓史,低危为两者均无。
  • 治疗:定期放血使血细胞比容目标<45%,联合每日一次或两次阿司匹林81 mg(无禁忌时),无论风险类别。
  • 降细胞治疗用于高危疾病,一线首选羟基脲和聚乙二醇干扰素α,二线为白消安和芦可替尼。
  • 有静脉血栓史患者建议全身抗凝。

临床怎么用

  • 所有患者无论风险类别,采用放血使血细胞比容<45%联合阿司匹林81 mg(无禁忌时)作为治疗骨干。
  • 高危患者行降细胞治疗,一线首选羟基脲或聚乙二醇干扰素α,二线为白消安或芦可替尼。
  • 有静脉血栓史患者建议全身抗凝。
  • 作者不将药物诱导的JAK2V617F等位基因负荷下降作为疾病修饰活性指标或治疗选择依据,除非伴有细胞遗传学和独立验证的形态学缓解。
  • 综述还包括妊娠、内脏静脉血栓、瘙痒、围手术期护理和post-PV MF的具体治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Polycythemia vera (PV) is a JAK2-mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and increased risk of thrombosis and progression into myelofibrosis (post-PV MF) or acute myeloid leukemia (AML). DIAGNOSIS: A working diagnosis is considered in the presence of a JAK2 mutation associated with hemoglobin/hematocrit levels of >16.5 g/dL/49% in men or 16 g/dL/48% in women; morphologic confirmation by bone marrow examination is advised but not mandated. CYTOGENETICS: Abnormal karyotype is seen in 15%-20% of patients with the most frequent sole abnormalities being +9 (5%), loss of chromosome Y (4%), +8 (3%), and 20q- (3%). MUTATIONS: Over 50% of patients harbor DNA sequence variants/mutations other than JAK2, with the most frequent being TET2 (18%) and ASXL1 (15%). Prognostically adverse mutations include SRSF2, IDH2, RUNX1, and U2AF1, with a combined incidence of 5%-10%. SURVIVAL AND PROGNOSIS: Median survival is ⁓15 years but exceeds 35 years for patients aged ≤40 years. Risk factors for survival include older age, leukocytosis, abnormal karyotype, and the presence of adverse mutations. Twenty-year risk for thrombosis, post-PV MF, or AML are ⁓26%, 16% and 4%, respectively. RISK FACTORS FOR THROMBOSIS: Two risk categories are considered: high (age >60 years or thrombosis history) and low (absence of both risk factors). Additional predictors for arterial thrombosis include cardiovascular risk factors and for venous thrombosis higher absolute neutrophil count and JAK2V617F allele burden. TREATMENT: Current goal of therapy is to prevent thrombosis. Periodic phlebotomy, with a hematocrit target of <45%, combined with once- or twice-daily aspirin (81 mg) therapy, absent contraindications, is the backbone of treatment in all patients, regardless of risk category. Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-α and second-line busulfan and ruxolitinib. In addition, systemic anticoagulation is advised in patients with venous thrombosis history. ADDITIONAL TREATMENT CONSIDERATIONS: At the present time, we do not consider a drug-induced reduction in JAK2V617F allele burden, which is often incomplete and seen not only with peg-IFN but also with ruxolitinib and busulfan, as an indicator of disease-modifying activity, unless accompanied by cytogenetic and independently-verified morphologic remission. Accordingly, we do not use the specific parameter to influence treatment choices. The current review also includes specific treatment strategies in the context of pregnancy, splanchnic vein thrombosis, pruritus, perioperative care, and post-PV MF.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023. PMID: 37357958. doi:10.1002/ajh.27002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。